Equities analysts expect FibroGen Inc (NASDAQ:FGEN) to post earnings per share of ($0.27) for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for FibroGen’s earnings. The highest EPS estimate is $0.46 and the lowest is ($0.65). FibroGen reported earnings per share of ($0.28) in the same quarter last year, which would suggest a positive year-over-year growth rate of 3.6%. The company is expected to announce its next earnings results on Tuesday, August 6th.
On average, analysts expect that FibroGen will report full-year earnings of ($0.87) per share for the current year, with EPS estimates ranging from ($1.22) to ($0.52). For the next year, analysts forecast that the company will report earnings of ($0.53) per share, with EPS estimates ranging from ($2.81) to $1.24. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that follow FibroGen.
FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.15. The business had revenue of $23.90 million during the quarter, compared to analyst estimates of $20.44 million. FibroGen had a negative net margin of 44.14% and a negative return on equity of 17.71%. The firm’s revenue was down 25.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.50) earnings per share.
Shares of NASDAQ FGEN traded down $0.65 during mid-day trading on Friday, reaching $40.68. The company had a trading volume of 623,355 shares, compared to its average volume of 768,032. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.16 and a quick ratio of 6.16. The firm has a market capitalization of $3.46 billion, a price-to-earnings ratio of -39.50 and a beta of 1.75. FibroGen has a 12-month low of $33.51 and a 12-month high of $68.55.
In other FibroGen news, CEO Thomas B. Neff sold 39,636 shares of the stock in a transaction that occurred on Thursday, March 21st. The stock was sold at an average price of $55.52, for a total transaction of $2,200,590.72. Following the transaction, the chief executive officer now owns 2,596,440 shares in the company, valued at $144,154,348.80. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Thomas B. Neff sold 18,400 shares of the stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $46.81, for a total value of $861,304.00. Following the transaction, the chief executive officer now owns 2,550,176 shares in the company, valued at approximately $119,373,738.56. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 251,495 shares of company stock worth $11,234,313. Insiders own 8.96% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the business. Lindbrook Capital LLC grew its holdings in FibroGen by 150.0% during the first quarter. Lindbrook Capital LLC now owns 500 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 300 shares during the last quarter. American International Group Inc. grew its stake in shares of FibroGen by 1.0% in the fourth quarter. American International Group Inc. now owns 50,074 shares of the biopharmaceutical company’s stock worth $2,317,000 after acquiring an additional 478 shares during the last quarter. BBR Partners LLC grew its stake in shares of FibroGen by 7.6% in the fourth quarter. BBR Partners LLC now owns 7,056 shares of the biopharmaceutical company’s stock worth $327,000 after acquiring an additional 500 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. grew its stake in shares of FibroGen by 15.9% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,756 shares of the biopharmaceutical company’s stock worth $205,000 after acquiring an additional 515 shares during the last quarter. Finally, FTB Advisors Inc. acquired a new stake in shares of FibroGen in the first quarter worth $27,000. Institutional investors own 66.27% of the company’s stock.
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Further Reading: What Are Cryptocurrencies?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.